RA Capital Management

company

Investments

Number of Investments
Number of Lead Investments
41
15
RA Capital Management has made 41 investments. Their most recent investment was on Dec 7, 2022, when Apogee Therapeutics, Inc raised
Date Company Name Round Money Raised Industry Lead Investor
Dec 7, 2022 Apogee Therapeutics Series B Biotechnology
Dec 7, 2022 Vor Biopharma Post-IPO Equity Biotechnology Yes
Nov 15, 2022 Jnana Therapeutics Series C Biotechnology
Nov 14, 2022 MBX Biosciences Series B Biotechnology
Sep 12, 2022 Nimbus Therapeutics Series Unknown Biotechnology
Aug 2, 2022 Empatica Series B Artificial Intelligence Yes
Mar 31, 2022 Incyclix Bio Series B Biotechnology
Feb 22, 2022 Somatus Series E Health Care
Feb 16, 2022 Star Therapeutics Series Unknown
Jan 25, 2022 Metagenomi Series B Artificial Intelligence
Dec 7, 2021 Freenome Series D Biotechnology Yes
Aug 18, 2021 Jnana Therapeutics Series B Biotechnology Yes
Jul 13, 2021 Nimbus Therapeutics Series Unknown Biotechnology
Jun 29, 2021 Element Biosciences Series C Biotechnology
Apr 29, 2021 Forge Biologics Series B Biotechnology Yes
Apr 15, 2021 Alchemab Therapeutics Series A Biotechnology Yes
Mar 31, 2021 Scribe Therapeutics Series B Biotechnology
Mar 1, 2021 Tenaya Therapeutics Series C Biopharma
Jan 19, 2021 Verve Therapeutics Series B Biotechnology
Nov 12, 2020 Metagenomi Series A Artificial Intelligence Yes
Oct 14, 2020 Nimbus Therapeutics Series Unknown Biotechnology
Aug 26, 2020 Freenome Series C Biotechnology
Jul 7, 2020 Vor Biopharma Series B Biotechnology Yes
Jun 26, 2020 Element Biosciences Series B Biotechnology
Jun 15, 2020 Novavax Post-IPO Equity Biotechnology Yes
Dec 5, 2019 Black Diamond Therapeutics Series C Biotechnology
Jul 24, 2019 Freenome Series B Biotechnology Yes
Feb 14, 2019 Vor Biopharma Series A Biotechnology Yes
Jan 9, 2019 Black Diamond Therapeutics Series B Biotechnology Yes
Nov 27, 2017 Medeor Therapeutics Series B Biotechnology Yes
Jan 6, 2017 AgriMetis Series B Agriculture Yes
Jul 18, 2016 Ardelyx Post-IPO Equity Biotechnology
Apr 13, 2016 Kala Pharmaceuticals Series C Biotechnology
Jul 22, 2015 KalVista Pharmaceuticals Series B Biotechnology Yes
Jun 22, 2015 Ardelyx Post-IPO Equity Biotechnology
Apr 6, 2015 Natera Series F Biotechnology
Jan 5, 2015 Moderna Therapeutics Series E Biotechnology
Nov 12, 2014 Blueprint Medicines Series C Bioinformatics
Nov 6, 2013 Ocera Therapeutics Post-IPO Equity Biopharma
Jul 25, 2012 Bluebird Bio Series D Biotechnology
Jan 1, 2007 Eiger BioPharmaceuticals Seed Biotechnology